Navigation Links
Tackling Atrial Fibrillation and Associated Cardiovascular Risk
Date:11/4/2008

- RecordAF Registry Baseline Data and New Data from the Landmark ATHENA

Study
PARIS, Nov. 4 /PRNewswire/ --

Live Webcast Media Briefing - non-US media only

Wednesday 12 November 2008 - 14.00-15.00am CET

Background:

-- AF is a growing health concern directly responsible for increased

morbidity and mortality

-- There is a need for a global prospective database like RecordAF, which

takes a closer look at disease characteristics and how management of AF

affects cardiovascular (CV) outcomes

-- AF is associated with a high hospitalization burden - 70 percent of AF

management costs are driven by hospitalization costs (Ringborg et al.

Europace 2008; 10:403-11)

-- A further sub-analysis of the ATHENA trial was conducted:

-- to better understand the impact of dronedarone on hospitalization

of AF patients particularly on the number and duration of CV and

non CV hospitalization nights

-- An additional sub-analysis was also conducted to further explore

dronedarone's rhythm and rate controlling properties

-- The ATHENA study is the first AF trial designed to evaluate the effect

of an anti arrhythmic drug (AAD) on morbidity and mortality. It showed

that dronedarone (brand name Multaq(R)), a new AAD undergoing the

registration process, can significantly improve CV outcomes including

reducing the risk of hospitalization and death.

Register on-line in advance of the online event:

1. Go to https://sanofiaventismediabriefing.webex.com/sanofiaventismediabriefing/ons t age/g.php?d=702842657&t=a&EA=nburns%40webex.com&ET=6b1f2c181b8fa5176928ed1c 72 009c4d&ETR=8789fb6f20765cb360e4d0c88cea0f23 (due to the length of this URL, please copy a
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
2. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
3. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
4. Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
7. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
8. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)...  Holographic Optical Technologies of Augusta, Georgia ... imaging, is entering the world of consumer electronics with ... 20 th , 2015, the campaign will introduce the ... 22-inch displays will allow consumers to view fully three ... addition to the two displays, the company will also ...
(Date:3/27/2015)... , March 27, 2015 A new report from ... America – Chile , ... are top targets for IVD firms.  The healthcare research firm ... into IVD strategies for the Latin American continent with a ... globally distributed supply operations. However, the country,s regional economic clout ...
(Date:3/27/2015)... 27, 2015 Report Details  ... ophthalmic drug companies  What does the future ... industry ? Visiongain,s brand new report shows you potential ... there. Our 242-page report provides 185 tables, ... the industry and the future market prospects. Our new ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
... Sept. 27, 2011 Dr. David Samadi, Vice Chairman, Department ... at The Mount Sinai Medical Center, has performed over 3,500 ... for prostate cancer . Robotics is among the latest ... to prostate cancer treatment , the options are vast ...
... GUANGZHOU, China, Sept. 27, 2011 /PRNewswire-Asia/ -- ... "Company"), a leading manufacturer, developer and distributor ... and other health products in the People,s ... has appointed PricewaterhouseCoopers (“PwC”) as the Company’s ...
Cached Medicine Technology:Prostate Cancer Treatment: Match Between CyberKnife And Robotic Prostate Surgery And The Winner Is? 2Prostate Cancer Treatment: Match Between CyberKnife And Robotic Prostate Surgery And The Winner Is? 3China Medicine Corporation Appoints PricewaterhouseCoopers As Independent Auditor To Audit Results For Fiscal Years 2006 - 2010 2
(Date:3/28/2015)... Genomic medicine experts have sequenced the genomes of ... time, key information for understanding and treating this intractable ... story on the Surviving Mesothelioma website. , ... British Columbia Cancer Agency, and PhenoPath lab in Seattle, ... and mutations that can lead to peritoneal mesothelioma ...
(Date:3/28/2015)... March 28, 2015 Lately the ... regarding recent changes and proposals around the NCAA. In ... and former collegiate student-athletes across a spectrum of universities ... on common challenges. The special panel consists of athletes ... sports ranging from football, track and field, baseball, and ...
(Date:3/28/2015)... 28, 2015 Healthpointe’s otolaryngologists, medical practitioners ... throat disorders, are now offering a wide variety ... which is characterized by the presence of phantom sounds ... people, tinnitus is a prevalent symptom that can arise ... is non-fatal, tinnitus can impede a person’s quality of ...
(Date:3/28/2015)... 28, 2015 Designers and Professionals of ... entitled Scratches 5K from Pixel Film Studios. , “Scratches ... any media inside Final Cut Pro X” Said Christina ... time and is an effective tool for any FCPX ... Scratches 5K's intuitive grunge overlays. Simply drag title layers ...
(Date:3/28/2015)... 28, 2015 Purity Products®, a ... announces the release of their revolutionary new weight ... two randomized, double-blind, placebo-controlled clinical studies to be ... hip size. MuffinStop™ is a combination of two ... mangostana, fused together to create one of the ...
Breaking Medicine News(10 mins):Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2
... Spanish psychologists and a German neurologist have recently shown that ... noun is different from the part used when a verb ... using functional magnetic resonance, according to an article they have ... "Learning nouns activates the left fusiform gyrus, while learning verbs ...
... not helped patients, says AMA president , THURSDAY, Feb. 25 ... vanishing, according to an American Medical Association report that looked ... In 24 of the states, the two largest insurers had ... year, 18 of 42 states had that type of market ...
... ... ... Advans, a solution provider and IT consulting firm, has announced today, the results of ... IT Outsourcing Survey, 75 percent of executives prefer outsourcing domestically rather than offshore. ...
... ... Sports Medicine (AOSSM), in partnership with Genzyme Biosurgery, is pleased to announce a new ... OA progression. , ... Rosemont, IL (Vocus) February 25, 2010 -- The American Orthopaedic Society for Sports ...
... ... Distributors continue to await their orders of Xyngular Xyng™ as Zija,s ... beat Xyngular™ to market months before their NEW! Xyng™ product was ... since. People from all over the world are calling to become ...
... ... clean hands and defense against colds and H1N1 flu virus as near as your closest ... to prevent infection and illness. Now teachers in classrooms anywhere can encourage frequent hot-water hand-washing ... ...
Cached Medicine News:Health News:Nouns and verbs are learned in different parts of the brain 2Health News:Nouns and verbs are learned in different parts of the brain 3Health News:Health Insurance Competition Vanishing: Study 2Health News:Advans Survey Reveals that 75 Percent of Executives Prefer Domestic Outsourcing vs. Offshore 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 3Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 2Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 3Health News:Angeles Launches New Portable Hot Water Sinks 2Health News:Angeles Launches New Portable Hot Water Sinks 3Health News:Angeles Launches New Portable Hot Water Sinks 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: